[go: up one dir, main page]

WO2003064394A8 - Heterocycles pentagonaux utilises en tant qu'agents antiviraux - Google Patents

Heterocycles pentagonaux utilises en tant qu'agents antiviraux

Info

Publication number
WO2003064394A8
WO2003064394A8 PCT/EP2003/000376 EP0300376W WO03064394A8 WO 2003064394 A8 WO2003064394 A8 WO 2003064394A8 EP 0300376 W EP0300376 W EP 0300376W WO 03064394 A8 WO03064394 A8 WO 03064394A8
Authority
WO
WIPO (PCT)
Prior art keywords
antiviral agents
ring heterocycles
heterocycles used
production
medicines used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/000376
Other languages
German (de)
English (en)
Other versions
WO2003064394A1 (fr
Inventor
Tobias Wunberg
Ulrich Betz
Gerald Kleymann
Susanne Nikolic
Juergen Reefschlaeger
Rudolf Schohe-Loop
Holger Zimmermann
Franz Zumpe
Wolfgang Bender
Kerstin Henninger
Guy Hewlett
Axel Jensen
Joerg Keldenich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to CA002474456A priority Critical patent/CA2474456A1/fr
Priority to EP03734671A priority patent/EP1472229A1/fr
Priority to JP2003564017A priority patent/JP2005521669A/ja
Priority to AU2003239243A priority patent/AU2003239243A1/en
Publication of WO2003064394A1 publication Critical patent/WO2003064394A1/fr
Publication of WO2003064394A8 publication Critical patent/WO2003064394A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des hétérocycles pentagonaux, à leur procédé de production ainsi qu'à leur utilisation pour produire des médicaments servant à traiter et/ou prévenir des maladies, et en particulier à leur utilisation en tant qu'agents antiviraux, en particulier contre des cytomégalovirus.
PCT/EP2003/000376 2002-01-28 2003-01-16 Heterocycles pentagonaux utilises en tant qu'agents antiviraux Ceased WO2003064394A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002474456A CA2474456A1 (fr) 2002-01-28 2003-01-16 Heterocycles pentagonaux utilises en tant qu'agents antiviraux
EP03734671A EP1472229A1 (fr) 2002-01-28 2003-01-16 Heterocycles pentagonaux utilises en tant qu'agents antiviraux
JP2003564017A JP2005521669A (ja) 2002-01-28 2003-01-16 抗ウイルス剤として使用するための５員ヘテロ環
AU2003239243A AU2003239243A1 (en) 2002-01-28 2003-01-16 5-ring heterocycles used as antiviral agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10203086A DE10203086A1 (de) 2002-01-28 2002-01-28 5-Ring Heterozyklen
DE10203086.3 2002-01-28

Publications (2)

Publication Number Publication Date
WO2003064394A1 WO2003064394A1 (fr) 2003-08-07
WO2003064394A8 true WO2003064394A8 (fr) 2003-12-24

Family

ID=7713161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000376 Ceased WO2003064394A1 (fr) 2002-01-28 2003-01-16 Heterocycles pentagonaux utilises en tant qu'agents antiviraux

Country Status (6)

Country Link
EP (1) EP1472229A1 (fr)
JP (1) JP2005521669A (fr)
AU (1) AU2003239243A1 (fr)
CA (1) CA2474456A1 (fr)
DE (1) DE10203086A1 (fr)
WO (1) WO2003064394A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ554119A (en) * 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide
ES2717941T3 (es) 2013-02-19 2019-06-26 Senomyx Inc Compuestos útiles como moduladores de TRPM8

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8101067A1 (es) * 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
EA000828B1 (ru) * 1995-12-14 2000-04-24 Мерк Энд Ко., Инк. Антагонисты гонадотропин-высвобождающего фактора
IL136768A0 (en) * 1997-12-22 2001-06-14 Bayer Ag INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

Also Published As

Publication number Publication date
AU2003239243A1 (en) 2003-09-02
WO2003064394A1 (fr) 2003-08-07
CA2474456A1 (fr) 2003-08-07
JP2005521669A (ja) 2005-07-21
DE10203086A1 (de) 2003-07-31
EP1472229A1 (fr) 2004-11-03

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
WO2005063734A3 (fr) Thiophenes substitues
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
WO2003080582A3 (fr) Derives de fredericamycine
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2005039504A3 (fr) Composes et methodes permettant de traiter les maladies et etats pathologiques lies au recepteur 2 de type toll
WO2004071382A3 (fr) Heterocycles substitues
WO2003088748A8 (fr) Utilisation d'heme-oxygenase-1 et produits de degradation d'heme
CA2474510A1 (fr) Heterocycles tricycliques fusionnes utilises dans le traitement de troubles hyperproliferatifs
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
WO2003033557A3 (fr) Copolymeres fluores, leur production et leur utilisation
NO20033318L (no) 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
ATE380188T1 (de) Substituierte chinolone
WO2006089664A3 (fr) Imidazoles substitues par heterocyclylamide
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
WO2005047278A3 (fr) Dihydroquinazolines ii substituees
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
WO2003024996A3 (fr) Macrocycles antibacteriens
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
WO2003064394A8 (fr) Heterocycles pentagonaux utilises en tant qu'agents antiviraux
WO2004112690A3 (fr) Derives de 2-aminobenzoyle
EP1469844A4 (fr) Procede et compose pour la prophylaxie ou le traitement d'une condition d'immunodeficience, telle que le sida

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 32/2003 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT?S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II))."

WWE Wipo information: entry into national phase

Ref document number: 2003734671

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2474456

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003564017

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003734671

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642